AR067491A1 - Preparacion recubierta - Google Patents

Preparacion recubierta

Info

Publication number
AR067491A1
AR067491A1 ARP080102957A ARP080102957A AR067491A1 AR 067491 A1 AR067491 A1 AR 067491A1 AR P080102957 A ARP080102957 A AR P080102957A AR P080102957 A ARP080102957 A AR P080102957A AR 067491 A1 AR067491 A1 AR 067491A1
Authority
AR
Argentina
Prior art keywords
preparation
pioglitazone
salts
pharmaceutically acceptable
coating layer
Prior art date
Application number
ARP080102957A
Other languages
English (en)
Inventor
Hiroto Bando
Yoshihiro Omachi
Kenichiro Kiyoshima
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of AR067491A1 publication Critical patent/AR067491A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Preparacion que contiene pioglitazona o una de sus sales como un ingrediente activo, que muestra alta biodisponibilidad de pioglitazona y menor dispersion interindividual en la concentracion del fármaco en sangre, así como una preparacion con cambio de color suprimido durante la conservacion. La presente provee una preparacion que contiene una partícula recubierta que contiene un nucleo con un ácido orgánico farmacéuticamente aceptable con hidrosolubilidad a 20°C no inferior a 10 mg/mL y un logaritmo comun negativo pKa1 de la primera constante de disociacion de ácido Ka1 a 25°C no superior a 5, y una capa de recubrimiento con pioglitazona o una de sus sales, así como dicha preparacion en la que una capa de recubrimiento contiene manitol o trehalosa. Reivindicacion 3: La preparacion de acuerdo con la reivindicacion 1, caracterizado porque el ácido orgánico farmacéuticamente aceptable es ácido cítrico. Reivindicacion 8: La preparacion de acuerdo con la reivindicacion 7, caracterizado porque el derivado celulosico es hidroxipropilcelulosa de baja sustitucion.
ARP080102957A 2007-07-12 2008-07-10 Preparacion recubierta AR067491A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007183749 2007-07-12

Publications (1)

Publication Number Publication Date
AR067491A1 true AR067491A1 (es) 2009-10-14

Family

ID=40228658

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080102957A AR067491A1 (es) 2007-07-12 2008-07-10 Preparacion recubierta

Country Status (6)

Country Link
US (1) US9427434B2 (es)
EP (1) EP2172200B1 (es)
JP (1) JP5350240B2 (es)
AR (1) AR067491A1 (es)
TW (1) TW200914006A (es)
WO (1) WO2009008487A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
JP5833922B2 (ja) 2008-08-12 2015-12-16 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
TW201113266A (en) * 2009-09-02 2011-04-16 Ziopharm Oncology Inc Pharmaceutical formulations for indibulin
AU2010302419B2 (en) * 2009-09-30 2014-07-31 Merck Sharp & Dohme (Uk) Limited Formulations for c-Met kinase inhibitors
GB201003766D0 (en) * 2010-03-05 2010-04-21 Univ Strathclyde Pulsatile drug release
EP2665479B1 (en) 2011-01-10 2019-06-26 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
WO2013055609A1 (en) 2011-10-12 2013-04-18 Merck Sharp & Dohme Corp. Pharmaceutical compositions that inhibit disproportionation
CA2852417A1 (en) * 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
WO2013106526A1 (en) * 2012-01-10 2013-07-18 Teva Pharmaceutical Industries Ltd. Saxagliptin parmaceutical formulations
ES2715382T3 (es) * 2013-06-17 2019-06-04 Nippon Soda Co Agente de recubrimiento que contiene hidroxialquilcelulosa

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0776172B2 (ja) * 1986-04-16 1995-08-16 藤沢薬品工業株式会社 マトリツクス錠
US5026560A (en) 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0832625B2 (ja) * 1987-01-29 1996-03-29 武田薬品工業株式会社 有核顆粒およびその製造法
JP3195391B2 (ja) 1991-11-14 2001-08-06 エスエス製薬株式会社 徐放性トラピジル錠
JPH05262767A (ja) 1992-03-19 1993-10-12 Takeda Chem Ind Ltd 持続性製剤
CN1072649C (zh) 1995-09-13 2001-10-10 武田药品工业株式会社 苯并氧杂吖庚因化合物,其生产方法和用途
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
US20010056177A1 (en) * 1997-12-20 2001-12-27 Becker Nathaniel T. Matrix granule
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2386517A1 (en) 1999-10-07 2001-04-12 Takeda Chemical Industries, Ltd. Amine derivatives
CA2407149C (en) 2000-04-28 2010-10-12 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist
AU2001256733A1 (en) 2000-05-16 2001-11-26 Takeda Chemical Industries Ltd. Melanin-concentrating hormone antagonist
CA2424770A1 (en) 2000-10-06 2003-04-03 Takeda Chemical Industries, Ltd. Solid pharmaceutical preparation
JP4284017B2 (ja) 2000-10-06 2009-06-24 武田薬品工業株式会社 固形製剤
IL159695A0 (en) * 2001-07-06 2004-06-20 Computer Ass Think Inc System and method for managing object based clusters
EP1437351A4 (en) 2001-10-19 2005-06-01 Takeda Pharmaceutical AMINE DERIVATIVE
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
US20040137052A1 (en) 2001-12-25 2004-07-15 Yoshihiro Uchiyama Acid-containing preparations
DE10209982A1 (de) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe
CN100367960C (zh) 2002-07-11 2008-02-13 武田药品工业株式会社 包衣制剂的制备方法
CA2514539C (en) * 2003-01-29 2012-03-06 Takeda Pharmaceutical Company Limited Process for producing coated preparation
US20050074494A1 (en) * 2003-10-06 2005-04-07 Xiu-Xiu Cheng Itraconazole immediate release formulation
US20060089387A1 (en) * 2004-10-26 2006-04-27 Le Huang Stabilized pharmaceutical composition comprising antidiabetic agent
WO2007126136A2 (en) * 2006-04-27 2007-11-08 Takeda Pharmaceutical Company Limited Mask- tasting solid preparation of pioglitazone

Also Published As

Publication number Publication date
TW200914006A (en) 2009-04-01
JPWO2009008487A1 (ja) 2010-09-09
JP5350240B2 (ja) 2013-11-27
EP2172200A4 (en) 2010-07-28
US20100166853A1 (en) 2010-07-01
WO2009008487A1 (ja) 2009-01-15
US9427434B2 (en) 2016-08-30
EP2172200A1 (en) 2010-04-07
EP2172200B1 (en) 2015-09-16

Similar Documents

Publication Publication Date Title
AR067491A1 (es) Preparacion recubierta
ES2545395T3 (es) Asociación de ivermectina con brimonidina para el tratamiento o prevención de la rosácea
Kryshchyshyn et al. Trends in research of antitrypanosomal agents among synthetic heterocycles
CY1122516T1 (el) Ετοιμες προς χρηση διατυπωσεις κετορολακης
ES2631980T3 (es) Formas de dosificación orales farmacéuticas que comprenden dabigatrán etexilato y sus sales farmacéuticamente aceptables
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
SMT201300096B (it) Inibitori di prolil idrossilasi
CO6382125A2 (es) Inhibidores de proteína quinasa
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
ES2573539T3 (es) Inhibidor de la cristalización y su uso en cápsulas de gelatina
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
JP2015506989A5 (es)
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
CO6650415A2 (es) Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa
RU2010139958A (ru) Стабилизированная фармацевтическая композиция, cодержащая доцетаксель
US20150164910A1 (en) Antiviral compounds and methods of use
CO2019004190A2 (es) Formulaciones liposomales para uso en el tratamiento del cáncer
JP2016539921A5 (es)
RU2015102772A (ru) Бензодиазелипы для мелкоклеточного рака легкого
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
ECSP12011699A (es) Tableta
RU2016147362A (ru) Препараты жидкого концетрата циклофосфамида

Legal Events

Date Code Title Description
FB Suspension of granting procedure